Reports

Current Report ESPI 8/2025
26/03/2025

Dosing of the first patient in the JASPIS-01 phase II study of dapolsertib (MEN1703/SEL24) for the treatment of patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL)

2025

Current Report ESPI 7/2025
26/03/2025

Preclinical data on synthetic lethality programs to be presented at the 2025 AACR Annual Meeting

2025

Current Report ESPI 6/2025
25/02/2025

Disclosure of delayed inside information regarding the decision to commence the collective redundancy process in the Company and the commencement of the consultation procedure with representatives of the Company’s employees

2025

Current Report ESPI 5/2025
25/02/2025

Ryvu Therapeutics announces strategic reorganization to extend the cash runway for the development of RVU120 and the preclinical pipeline

2025

Current Report ESPI 04/2025
17/02/2025

Conclusion of funding agreement with the Małopolska Centre for Entrepreneurship

2025

Current Report ESPI 3/2025
07/02/2025

Recommendation of Ryvu’s project for funding by the Medical Research Agency

2025

Current Report ESPI 2/2025
07/02/2025

Recommendation of Ryvu’s project for funding by the Medical Research Agency

2025

Current Report ESPI 1/2025
30/01/2025

Termination of STING program under Research Collaboration Option and Exclusive License Agreement with BioNTech SE

2025

Current Report ESPI 38/2024
12/12/2024

Clinical update on RVU120 Phase II program

2024

Current Report ESPI 37/2024
05/12/2024

Dosing of the first patient in the POTAMI-61 Phase II Study of RVU120 for the Treatment of Patients with Myelofibrosis (MF)

2024

Current Report ESPI 36/2024
02/12/2024

Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program

2024

Current Report ESPI 35/2024
02/12/2024

Recommendation of Ryvu’s project for funding by the Małopolska Centre for Entrepreneurship

2024

Current Report ESPI 34/2024
19/11/2024

Publication dates for periodic reports in 2025

2024

Current Report ESPI 33/2024
19/11/2024

Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program – Article 19 of MAR

2024

Current Report ESPI 32/2024
23/10/2024

Clinical and preclinical data on RVU120, RVU305, WRN and synthetic lethality platform presented at the 2024 EORTC-NCI-AACR Symposium

2024

Current Report ESPI 31/2024
22/10/2024

Conclusion of an agreement in the area of operational execution of MEN1703 (SEL24) Phase II clinical trial in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL)

2024

Current Report ESPI 30/2024
09/10/2024

Clinical and preclinical data on RVU120, RVU305, WRN and synthetic lethality platform to be presented at the 2024 EORTC-NCI-AACR Symposium

2024

Current Report ESPI 29/2024
19/09/2024

Dosing of the first patient in the REMARK Phase II Study of RVU120 for the Treatment of Anemia in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS)

2024

Current Report ESPI 28/2024
11/09/2024

Continuation of the development of PRMT5 program

2024

Current Report ESPI 27/2024
29/08/2024

Fulfillment of conditions for the disbursement of the Tranche C of financing from the European Investment Bank

2024

Current Report ESPI 26/2024
27/06/2024

Shareholders controlling at least 5% of the votes at the General Shareholders Meeting of Ryvu Therapeutics S.A. convened on June 27th, 2024

2024

Current Report ESPI 25/2024
27/06/2024

Resolutions adopted by the General Shareholders Meeting of Ryvu Therapeutics S.A.

2024

Current Report ESPI 24/2024
19/06/2024

Fulfillment of conditions for the disbursement of the Tranche B of financing from the European Investment Bank

2024

Current Report ESPI 23/2024
14/06/2024

Ryvu Therapeutics presents clinical and preclinical data on RVU120 at the 2024 European Hematology Association Congress

2024

Current Report ESPI 22/2024
14/06/2024

Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program

2024

Current Report ESPI 21/2024
04/06/2024

Conclusion of funding agreement with the Polish Agency for Enterprise Development

2024

Current Report ESPI 20/2024
29/05/2024

Convening the Ordinary General Shareholders Meeting of Ryvu Therapeutics S.A.

2024

Current Report ESPI 19/2024
29/05/2024

Obtaining the status of Associate Partner within IPCEI Med4Cure

2024

Current Report ESPI 18/2024
28/05/2024

Conclusion of funding agreement with the National Centre for Research and Development

2024

Current Report ESPI 17/2024
23/05/2024

Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program – Article 19 of MAR

2024

Current Report ESPI 16/2024
14/05/2024

Preclinical and clinical data on RVU120 to be presented at the 2024 European Hematology Association Congress

2024

Current Report ESPI 15/2024
10/04/2024

Posters on preclinical data on RVU120 and Synthetic Lethality Programs presented at the 2024 AACR Annual Meeting

2024

Current Report ESPI 14/2024
29/03/2024

Conclusion of an agreement in the area of operational execution of RVU120 Phase II clinical trial in myelofibrosis

2024

Current Report ESPI 13/2024
27/03/2024

Ryvu project recommended for funding by the Polish Agency for Enterprise Development

2024

Current Report ESPI 12K/2024
08/03/2024

Correction of the current report No. 12/2024 of March 6, 2024 – correction of obvious typographical error

2024

Current Report ESPI 12/2024
06/03/2024

Fulfillment of conditions for the disbursement of the Tranche A of financing from the European Investment Bank

2024

Current Report ESPI 11/2024
06/03/2024

Preclinical data on RVU120 and Synthetic Lethality Programs to be presented at the 2024 AACR Annual Meeting

2024

Current Report ESPI 10/2024
14/02/2024

Dosing of the first patient in the RIVER-52 Phase II Study of RVU 120 as a monotherapy for the treatment of patients with relapsed/refractory AML and HR-MDS

2024

Current Report ESPI 9/2024
09/02/2024

Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program

2024

Current Report ESPI 8/2024
07/02/2024

Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program – Article 19 of MAR

2024

Current Report ESPI 7/2024
05/02/2024

Achievement of the second milestone under license agreement with Exelixis Inc.

2024

Current Report ESPI 6/2024
05/02/2024

Notification from a person discharging managerial responsibilities in the Company – Article 19 of MAR

2024

Current Report ESPI 5/2024
31/01/2024

Dosing of the first patient in the RIVER-81 Phase II study of RVU120 in combination with venetoclax

2024

Current Report ESPI 4/2024
31/01/2024

Registration of series K subscription warrants of the Company with the National Depository for Securities

2024

Current Report ESPI 3/2024
18/01/2024

Publication dates for periodic reports in 2024

2024

Current Report ESPI 2/2024
18/01/2024

Take-up of series K subscription warrants by the European Investment Bank

2024

Current Report ESPI 1/2024
03/01/2024

Resignation of a member of the Company’s Supervisory Board from his position

2024

Current Report ESPI 49/2023
11/12/2023

Presentation of preclinical data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Meeting and additional clinical update

2023

Current Report ESPI 48/2023
11/12/2023

Preclinical and clinical data on RVU120 presented at the 2023 American Society of Hematology (ASH) Annual Meeting

2023

Current Report ESPI 47/2023
07/12/2023

Preclinical data on RVU120 to be presented at the San Antonio Breast Cancer Symposium 2023

2023

Current Report ESPI 46/2023
02/11/2023

Clinical and preclinical data on RVU120 to be presented at the American Society of Hematology (ASH) Annual Meeting

2023

Current Report ESPI 45/2023
23/10/2023

Ryvu presents updated clinical Phase I/II data of RVU120 in patients with relapsed/refractory metastatic or advanced solid tumors at the ESMO Congress 2023 together with the RVU120 Development Plan update

2023

Current Report ESPI 44/2023
20/10/2023

Conclusion of a Clinical Trial Financial Support agreement for an investigator-initiated Phase II RVU120 study in Low-Risk Myelodysplastic Syndromes

2023

Current Report ESPI 43/2023
16/10/2023

RVU120 poster to be presented at the European Society for Medical Oncology ESMO Congress 2023

2023

Current Report ESPI 42/2023
16/10/2023

Posters on preclinical data on PRMT5 and Synthetic Lethality Platform presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference

2023

Current Report ESPI 41/2023
04/10/2023

Posters to be presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference

2023

Current Report ESPI 40/2023
14/09/2023

Conclusion of an amendment to global License Agreement with Menarini Group

2023

Current Report ESPI 39/2023
04/08/2023

Conclusion of two agreements in the area of operational execution of RVU120 Phase II clinical trials in hematology

2023

Current Report ESPI 38/2023
31/07/2023

Conclusion of a financing agreement with the Medical Research Agency

2023

Current Report ESPI 37/2023
31/07/2023

Conclusion of the agreement in the area of securing venetoclax supply chain for RVU120 Phase II clinical trial in combination therapy in hematology

2023

Current Report ESPI 36/2023
21/07/2023

Notification from a person discharging managerial responsibilities in the Company – Article 19 of MAR

2023

Current Report ESPI 35/2023
14/07/2023

Conclusion of two agreements in the area of data management and biostatistics for RVU120 Phase II clinical trials in hematology

2023

Current Report ESPI 34/2023
06/07/2023

Conclusion of two agreements with Zakłady Farmaceutyczne Polpharma S.A. in the area of RVU120 active substance (API) production for Phase II clinical trials

2023

Current Report ESPI 33/2023
19/06/2023

Registration of an amendment to the Articles of Association of the Company concerning conditional increase in the share capital of the Company

2023

Current Report ESPI 32/2023
14/06/2023

Appointment of new Members of the Supervisory Board of Ryvu Therapeutics S.A.

2023

Current Report ESPI 31/2023
14/06/2023

Shareholders controlling at least 5% of the votes at the General Shareholders Meeting of Ryvu Therapeutics S.A. convened on June 14th, 2023

2023

Current Report ESPI 30/2023
14/06/2023

Resolutions adopted by the General Shareholders Meeting of Ryvu Therapeutics S.A.

2023

Current Report ESPI 29/2023
13/06/2023

Recommendation of Ryvu’s project for funding by the Medical Research Agency

2023

Current Report ESPI 28/2023
09/06/2023

Publication of the updated clinical and preclinical data on RVU120

2023

Current Report ESPI 22K/2023
26/05/2023

Correction of the current report on the convening of the Company’s Annual General Meeting

2023

Current Report ESPI 27/2023
25/05/2023

Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program

2023

Current Report ESPI 26/2023
25/05/2023

Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program

2023

Current Report ESPI 25/2023
25/05/2023

Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program

2023

Current Report ESPI 24/2023
25/05/2023

Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program – Article 19 of MAR

2023

Current Report ESPI 23/2023
23/05/2023

Notification from a person discharging managerial responsibilities in the Company – Article 19 of MAR

2023

Current Report ESPI 22/2023
18/05/2023

Convening the Ordinary General Shareholders Meeting of Ryvu Therapeutics S.A.

2023

Current Report ESPI 21/2023
16/05/2023

Notification from PTE Allianz Polska S.A. of a change in its share in the total number of votes in the Company

2023

Current Report ESPI 20/2023
11/05/2023

New clinical and preclinical data on RVU120 to be presented at the upcoming 2023 European Hematology Association Congress

2023

Current Report ESPI 19/2023
05/05/2023

Conclusion of an agreement for the issuance of subscription warrants to the European Investment Bank

2023

Current Report ESPI 18/2023
20/04/2023

Conclusion of the agreements concerning Phase II start-up services for RVU120 clinical studies in AML/HR-MDS

2023

Current Report ESPI 17/2023
12/04/2023

Notification from a person discharging managerial responsibilities in the Company – Article 19 of MAR

2023

Current Report ESPI 16/2023
06/04/2023

Notice of termination regarding Option, License and Collaboration Agreement with Galapagos NV

2023

Current Report ESPI 15/2023
10/03/2023

Change of publication date of the annual report for 2022

2023

Current Report ESPI 14/2023
02/03/2023

Conclusion of an agreement concerning the operational execution of Phase II of Phase I/II clinical trial of RVU120 in Patients with Relapsed/Refractory Solid Tumors

2023

Current Report ESPI 13/2023
06/02/2023

Receipt from a person discharging managerial responsibilities in the Company of a correction to the Article 19 MAR notification

2023

Current Report ESPI 12/2023
03/02/2023

Notification from a person discharging managerial responsibilities in the Company – Article 19 of MAR

2023

Current Report ESPI 11/2023
03/02/2023

Notification from a person discharging managerial responsibilities in the Company – Article 19 of MAR

2023

Current Report ESPI 10/2023
26/01/2023

Achievement of the first milestone under licence agreement with Exelixis Inc.

2023

Current Report ESPI 07/2023
25/01/2023

Announcement of the NDS on registration of series J shares with the NDS

2023

Current Report ESPI 09/2023
25/01/2023

Publication dates for periodic reports in 2023

2023

Current Report ESPI 08/2023
25/01/2023

Notification from TFI Allianz Polska S.A. of a change in its share in the total number of votes in the Company

2023

Current Report ESPI 06/2023
20/01/2023

Admission and introduction of the series J shares of the Company to trading on the regulated market of the WSE

2023

Current Report ESPI 05/2023
20/01/2023

Conditional registration of the series J shares of the Company with the National Depository for Securities

2023

Current Report ESPI 04/2023
19/01/2023

Notification from a shareholder of a change in its share in the total number of votes in the Company

2023

Current Report ESPI 03/2023
18/01/2023

Notification from a shareholder of a change in his share in the total number of votes in the Company

2023

Current Report ESPI 02/2023
18/01/2023

Registration of amendment of the Company’s Articles of Association concerning share capital

2023

Current Report ESPI 01/2023
09/01/2023

Notification from PTE Allianz Polska S.A. of a change in its share in the total number of votes in the Company

2023

Current Report ESPI 35/2022
22/12/2022

Notification from a person discharging managerial responsibilities in the Company due to series J shares allotment – Article 19 of MAR

2022

Current Report ESPI 34/2022
22/12/2022

Notification from a person closely related to a person discharging managerial responsibilities in the Company due to series J shares allotment – Article 19 of MAR

2022

Current Report ESPI 33/2022
22/12/2022

Summary of the subscription of ordinary bearer series J shares

2022

Current Report ESPI 32/2022
22/12/2022

Allotment of series J shares

2022

Current Report ESPI 31/2022
15/12/2022

Determination of the final issue price of series J shares and the final number of series J shares that will be offered in the public offering

2022

Current Report ESPI 30/2022
11/12/2022

Ryvu Therapeutics presents Clinical and Translational Data of RVU120 and SEL24 (MEN1703) at the 2022 American Society of Hematology (ASH) Annual Meeting

2022

Current Report ESPI 29/2022
07/12/2022

Approval of the prospectus of the Company

2022

Current Report ESPI 28/2022
02/12/2022

Decision to conduct public offering of J series shares in December 2022

2022

Current Report ESPI 27/2022
30/11/2022

Disclosure of delayed confidential information regarding the start of negotiations and the non-binding determination of the key terms of a potential collaboration

2022

Current Report ESPI 26/2022
30/11/2022

Execution of an exclusive Research Collaboration Option and Exclusive License Agreement and Equity Investment Agreement with BioNTech SE

2022

Current Report ESPI 25/2022
03/11/2022

Clinical and Translational Data of RVU120 and SEL24 (MEN1703) to be presented at the 2022 American Society of Hematology (ASH) Annual Meeting

2022

Current Report ESPI 24/2022
26/10/2022

Ryvu Therapeutics presents new clinical and preclinical data for RVU120 program at 34th AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium

2022

Current Report ESPI 23/2022
12/10/2022

Posters to be presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium

2022

Current Report ESPI 22/2022
05/10/2022

Adoption by the Company’s Management Board of a resolution on issuance of shares within the framework of authorized capital and conclusion of lock-up agreements

2022

Current Report ESPI 21/2022
03/10/2022

Registration of an amendment to the Company’s Articles of Association

2022

Current Report ESPI 20/2022
19/09/2022

Shareholders controlling at least 5% of the votes at the Extraordinary General Shareholders Meeting of Ryvu Therapeutics S.A. convened on September 19th, 2022

2022

Current Report ESPI 19/2022
19/09/2022

Resolutions adopted by the Extraordinary General Shareholders Meeting of Ryvu Therapeutics S.A.

2022

Current Report ESPI 18/2022
14/09/2022

Self-correction to the draft resolution of the General Meeting of Ryvu Therapeutics S.A. convened for September 19, 2022

2022

Current Report ESPI 17/2022
19/08/2022

Convening of the Extraordinary General Shareholders Meeting of Ryvu Therapeutics S.A.

2022

Current Report ESPI 16/2022
19/08/2022

Ryvu Therapeutics’ development plans for 2022-2024

2022

Current Report ESPI 15/2022
18/08/2022

Change of the date of publication of the periodic report for the first half of 2022

2022

Current Report ESPI 14/2022
17/08/2022

Conclusion of a financing agreement with the European Investment Bank

2022

Current Report ESPI 13/2022
26/07/2022

Changes in Ryvu’s Management Board

2022

Current Report ESPI 12/2022
08/07/2022

Information on a potential supply of shares in connection with the expiration of the lock-up period for shares under the Stock Grant Program

2022

Current Report ESPI 11/2022
07/07/2022

Execution of an exclusive license agreement with Exelixis, Inc. to develop novel STING agonist-based targeted cancer therapies

2022

Current Report ESPI 10/2022
01/07/2022

Shareholders controlling at least 5% of the votes at the General Shareholders Meeting of Ryvu Therapeutics S.A. convened on June 30, 2022

2022

Current Report ESPI 09/2022
01/07/2022

Resolutions adopted by the General Shareholders Meeting of Ryvu Therapeutics S.A.

2022

Current Report ESPI 08/2022
10/06/2022

Publication of the updated phase 1b clinical and preclinical data for RVU120 and phase 1/2 SEL24 (MEN1703)

2022

Current Report ESPI 07/2022
03/06/2022

Convening the Ordinary General Shareholders Meeting of Ryvu Therapeutics S.A.

2022

Current Report ESPI 06/2022
12/05/2022

New data from RVU120 and SEL24(MEN1703) programs to be presented at the EHA Hybrid Congress 2022

2022

Current Report ESPI 05/2022
27/04/2022

Ryvu Therapeutics to present recent RVU120 and SEL24 (MEN1703) data at ASCO 2022 Annual Meeting

2022

Current Report ESPI 04/2022
01/04/2022

Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program – Article 19 of MAR

2022

Current Report ESPI 03/2022
08/03/2022

Ryvu Therapeutics to present recent data from oncology programs at AACR 2022 Annual Meeting

2022

Current Report ESPI 02/2022
19/01/2022

Publication dates for periodic reports in 2022

2022

Current Report ESPI 01/2022
19/01/2022

Delivery of a lawsuit for payment in connection with the construction of the Research and Development Center

2022

Current Report ESPI 40/2021
30/12/2021

Ryvu Therapeutics to receive from Menarini Group a development milestone based on an amended global License Agreement

2021

Current Report ESPI 39/2021
20/12/2021

Ryvu Therapeutics receives approval to conduct Phase I/II study of RVU120 (SEL120) in patients with relapsed/refractory metastatic or advanced solid tumors in Spain

2021

Current Report ESPI 38/2021
17/12/2021

Change order to the statement of work

2021

Current Report ESPI 37/2021
14/12/2021

Galapagos NV exercises its exclusive option to license program with therapeutic potential in inflammatory diseases

2021

Current Report ESPI 36/2021
13/12/2021

Ryvu Therapeutics Presents Clinical and Translational Data Updates at the 63rd American Society of Hematology (ASH) Annual Meeting and the 44th San Antonio Breast Cancer Symposium

2021

Current Report ESPI 35/2021
19/11/2021

Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program – Article 19 of MAR

2021

Current Report ESPI 34/2021
09/11/2021

Ryvu Therapeutics to highlight HPK1 and STING Programs at the upcoming SITC Conference

2021

Current Report ESPI 33/2021
04/11/2021

Ryvu’s partner Menarini Group receives FDA Orphan Drug Designation for SEL24 (MEN1703) for the Treatment of Acute Myeloid Leukemia

2021

Current Report ESPI 32/2021
04/11/2021

Clinical and Translational Data from RVU120 and SEL24(MEN1703) programs to be presented at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition and the 44th Annual San Antonio Breast Cancer Symposium (SABCS)

2021

Current Report ESPI 31/2021
24/09/2021

Filing a lawsuit against Mota-Engil Central Europe S.A. in connection with construction of the Research and Development Center

2021

Current Report ESPI 30/2021
25/08/2021

First Patient Dosed in Phase I/II Study of RVU120 (SEL120) in Patients with Relapsed/Refractory Metastatic or Advanced Solid Tumors

2021

Current Report ESPI 29/2021
25/08/2021

Resignation of the Member of the Management Board

2021

Current Report ESPI 28/2021
18/08/2021

Notification from Aviva Otwarty Fundusz Emerytalny Aviva Santander on exceeding the threshold of 5% of the total number of votes in the Company

2021

Current Report ESPI 27/2021
13/08/2021

Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program – Article 19 of MAR

2021

Current Report ESPI 26/2021
21/07/2021

Notification from person discharging managerial responsibilities in the Company – Article 19 of MAR

2021

Current Report ESPI 25/2021
14/07/2021

FDA lifts partial clinical hold on RVU120 (SEL120) Phase Ib study in acute myeloid leukemia and myelodysplastic syndrome

2021

Current Report ESPI 24/2021
13/07/2021

Notifications from persons discharging managerial responsibilities in the Company – Article 19 of MAR

2021

Current Report ESPI 23/2021
09/07/2021

Information on the change in the shareholder structure due to execution of the Stock Grant Program in the Company – Art. 69 of the Act on Offerings

2021

Current Report ESPI 22K/2021
08/07/2021

Correction of the current report No. 22/2021 of July 8, 2021

2021

Current Report ESPI 22/2021
08/07/2021

Conclusion of the share donation agreement between the Company and President of the Management Board and main shareholder of the Company in execution of a non-diluting incentive program in the Company

2021

Current Report ESPI 21/2021
30/06/2021

Shareholders controlling at least 5% of the votes at the General Shareholders Meeting of Ryvu Therapeutics S.A. convened on June, 29 2021

2021

Current Report ESPI 20/2021
30/06/2021

Resolutions adopted by the General Shareholders Meeting of Ryvu Therapeutics S.A.

2021

Current Report ESPI 19/2021
11/06/2021

Publication of clinical data for phase I RVU120 and phase I/II SEL24 (MEN1703)

2021

Current Report ESPI 18/2021
02/06/2021

Convening the Ordinary General Shareholders Meeting of Ryvu Therapeutics S.A.

2021

Current Report ESPI 18/2021
28/05/2021

Ryvu Therapeutics got full approval to conduct Phase I/II study of RVU120 (SEL120) in patients with relapsed/refractory metastatic or advanced solid tumors in Poland

2021

Current Report ESPI 16/2021
20/05/2021

Publication of abstract related to SEL24 (MEN1703) program at ASCO Annual Meeting 2021

2021

Current Report ESPI 15/2021
17/05/2021

Shareholders controlling at least 5% of the vote at the Extraordinary General Shareholders Meeting of Ryvu Therapeutics S.A. convened on May 17, 2021

2021

Current Report ESPI 14/2021
17/05/2021

Resolutions adopted by the Extraordinary General Shareholders Meeting of Ryvu Therapeutics S.A.

2021

Current Report ESPI 13/2021
13/05/2021

Information concerning impact of non-diluting incentive program on Company’s financial statements

2021

Current Report ESPI 12/2021
12/05/2021

New data from RVU120 and SEL24(MEN1703) programs to be presented at the EHA Congress 2021

2021

Current Report ESPI 10/2021
20/04/2021

Declaration of establishing a non-diluting incentive program in the Company for the years 2021-2024

2021

Current Report ESPI 09/2021
08/04/2021

Partial Clinical Hold of Phase Ib Clinical Trial of RVU120 (SEL120) by the FDA in Acute Myeloid Leukemia and Myelodysplastic Syndrome

2021

Current Report ESPI 08/2021
08/04/2021

Notification from person discharging managerial responsibilities in the Company – Article 19 of MAR

2021

Current Report ESPI 07/2021
18/03/2021

Conclusion of the grant agreement with the National Center for Research and Development

2021

Current Report ESPI 06/2021
11/03/2021

Ryvu Therapeutics to present recent data from multiple oncology programs at AACR 2021 Virtual Annual Meeting

2021

Current Report ESPI 05/2021
08/03/2021

Conclusion of an agreement concerning operational execution of Phase I clinical trial of RVU120 (SEL120) in solid tumors

2021

Current Report ESPI 04/2021
18/01/2021

Ryvu Therapeutics project regarding Phase I/II clinical study of SEL120 (RVU 120) in solid tumors recommended for financing by NCBiR

2021

Current Report ESPI 03/2021
13/01/2021

Publication dates for periodic reports in 2021

2021

Current Report ESPI 02/2021
07/01/2021

Ryvu Therapeutics to expand its Phase I study of SEL120 (RVU120) in patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome to Poland

2021

Current Report ESPI 01/2021
04/01/2021

The new Clinical Trial Application for the conduct of a Phase I/II study of RVU120 (SEL120) in patients with solid tumors submitted by Ryvu Therapeutics S.A.

2020

Current Report ESPI 43/2020
01/12/2020

Three Posters on SEL24/MEN1703 including Pharmacodynamic Data from the Dose Escalation Part of DIAMOND-01 Trial to be published at American Society of Hematology (ASH) Annual Meeting

2020

Current Report ESPI 42/2020
23/11/2020

Appointment of the new Management Board Member of Ryvu Therapeutics S.A.

2020

Current Report ESPI 40/2020
21/10/2020

Revision of the Company’s research project pipeline

2020

Current Report ESPI 39/2020
14/10/2020

Ryvu Therapeutics abstract concerning the STING program accepted for presentation at the SITC 2020

2020

Current Report ESPI 38/2020
12/10/2020

Change of the registered office address of Ryvu Therapeutics S.A.

2020

Current Report ESPI 36/2020
16/09/2020

First patient dosed in Europe within the Expansion Cohort of Phase I/II Clinical Study of SEL24/MEN1703

2020

Current Report ESPI 34/2020
01/09/2020

Appointment of Members of the Company’s Management and Supervisory Boards for a new term of office

2020

Current Report ESPI 33/2020
31/08/2020

Shareholders controlling at least 5% of the vote at the General Meeting of Ryvu Therapeutics S.A. held on August 31, 2020

2020

Current Report ESPI 32/2020
31/08/2020

Resolutions adopted by the Annual General Shareholders Meeting of Ryvu Therapeutics S.A.

2020

Current Report ESPI 31/2020
26/08/2020

Introduction of the Series I Shares to trading on the main market operated by the WSE and designation of the last day of listing of Rights to Series I Shares

2020

Current Report ESPI 29/2020
19/08/2020

Registration of share capital increase

2020

Current Report ESPI 28/2020
05/08/2020

Completion of the subscription of Series I Shares

2020

Current Report ESPI 26/2020
30/07/2020

Introduction of the Rights to Series I Shares to trading on the main market operated by the WSE

2020

Current Report ESPI 25/2020
27/07/2020

Registration of the Rights to Series I Shares in the book-entry form by the National Depository for Securities

2020

Current Report ESPI 24/2020
22/07/2020

Execution of subscription agreements and collection of cash contributions relating to series I shares in Ryvu Therapeutics S.A.

2020

Current Report ESPI 23/2020
15/07/2020

Determination of the issue price of Series I shares issued by Ryvu Therapeutics S.A., the number of Series I shares to be offered for subscription by Ryvu Therapeutics S.A. and execution of the pricing supplement to the placement agreement

2020

Current Report ESPI 22/2020
13/07/2020

Ryvu Therapeutics S.A. concludes a placement agreement and commences the book-building process for an offering by way of private subscription of new Series I ordinary bearer shares issued by Ryvu Therapeutics S.A.

2020

Current Report ESPI 21/2020
13/07/2020

Shareholders controlling at least 5% of the vote at the General Meeting of Ryvu Therapeutics S.A. convened on July, 13 2020

2020

Current Report ESPI 20/2020
13/07/2020

Resolutions adopted by the General Meeting of Ryvu Therapeutics S.A.

2020

Raport bieżący ESPI 18/2020
15/06/2020

Ryvu Therapeutics Strategy for 2020-2022

2020